Study demonstrates device-guided respiratory modulation, if used properly, can significantly improve NYHA classification and breathlessness of heart failure patients within 4 weeks. InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that European Journal of Heart Failure, a peer reviewed medical journal of the European Society of Cardiology, published the results of a 72-patients, randomized, controlled study which demonstrated that device-guided respiratory modulation with RESPeRATE applied at the home setting can significantly relieve symptoms of heart failure in elderly patients. Chronic heart failure (CHF) affects about 5 million patients in the U.S. alone. It is the most widespread cause of hospitalization of patients over 65, with over 1 million hospitalizations every year. The total cost of treating the disease is estimated at $33 billion annually. About 91% of CHF sufferers have a medical history involving hypertension.
